118 results on '"Pigozzo J"'
Search Results
2. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
3. 1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
4. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
5. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
6. Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)
7. Corrigendum: Melanoma in Adolescents and Young Adults (AYA): Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study (Front. Oncol, (2021), 11, (725523), 10.3389/fonc.2021.725523)
8. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
9. The prognostic impact of the extent of ulceration in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)
10. 1107P Clinical outcomes to checkpoint inhibitors in NRAS mutated metastatic melanoma (MM) compared with wild type BRAF/NRAS: An Italian Melanoma Intergroup (IMI) study
11. Corrigendum: Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. [Ann Oncol 27, (2016), (732-738)]
12. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
13. The prognostic impact of the extent of ulceration in patients with clinical stage I–II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI).
14. ANÁLISE EXPERIMENTAL E NUMÉRICA DE UMA GRELHA LAMELAR PLANA DE MADEIRA.
15. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases
16. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
17. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy
18. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
19. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy.
20. LBA69 - Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
21. LBA47 - Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
22. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
23. Predictors of Survival for Therapy with Ipilimumab in Metastatic Melanoma
24. Trans-Arterial Chemo-Embolization (Tace) with Cpt-11 Charged Microbeads in Metastatic Uveal Melanoma Patients: a Retrospective Analysis of 140 Patients with Liver Metastases
25. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
26. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
27. Efficacy and Safety of Ipilimumab Reinduction Therapy Patients with Pretreated Advanced Melanoma Participating in an Expanded Access Programme (EAP) in Italy
28. Metastatic Uveal Melanoma: A 22 Years Single Center Experience
29. Circulating tumor cells detection and evaluation of their apoptotic status in patients with localized breast cancer before and after surgery.
30. Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study
31. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
32. Toxicity of adjuvant treatment with high-dose interferon alpha 2b (HD-IFN) in high-risk stage III melanoma patients (pts): The Italian experience
33. Oxaliplatin (OX) and leucovorin (L) combined with protracted-infusion fluorouracil (F) and radiation (XRT) in locally advanced esophageal cancer (LAEC): A multicentric phase II study
34. 1114P - Trans-Arterial Chemo-Embolization (Tace) with Cpt-11 Charged Microbeads in Metastatic Uveal Melanoma Patients: a Retrospective Analysis of 140 Patients with Liver Metastases
35. 1098P - Predictors of Survival for Therapy with Ipilimumab in Metastatic Melanoma
36. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
37. Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
38. GI tumours. Which advances in esophageal cancer?
39. Endocrine toxicities after treatment with ipilimumab
40. The cost of unresectable stage III or stage IV melanoma in Italy
41. Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma
42. A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance.
43. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
44. Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants.
45. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
46. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
47. Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features.
48. Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach.
49. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
50. Corrigendum: Melanoma in Adolescents and Young Adults (AYA): Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.